News

CYP-001 is Cynata's lead Cymerus mesenchymal stem cell (MSC) product. Cynata plans to conduct the Phase 1 clinical trial, which is entitled "An Open-Label Phase 1 Study to Investigate

Redx scientists have demonstrated that the Porcupine inhibitor could have a crucial role in improving the immune system response of some cancer patients when used in combination with

In anticipation of substantial growth across Alnylam over the next five years, the office opens with a core Clinical Development, Regulatory Affairs, and Commercial team and space for

The phase III DURATION-8 trial showed that Bydureon, taken just once a week in combination with Forxiga once daily significantly reduced blood sugar, compared with the individual medicines

The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced. This is in addition to $50 million raised separately through

Under the terms of the collaboration, Dr. Reddy’s will commercialise XGEVA (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India. In 2015, Dr. Reddy’s announced an initial strategic collaboration with Amgen to

Under the license, TeneoBio will be able to use the OmniFlic technology from the OmniAb platform to discover fully human bispecific antibodies to be developed for the treatment of various

The CHMP adopted a positive opinion recommending approval of Pfizer's Ibrance (palbociclib) in combination with endocrine therapy to treat HR-positive, HER2-negative metastatic breast cancer. Its opinion specifies that

In the Resolve phase 3 trial of 11,856 older adults (60 years of age and older), the vaccine did not meet its efficacy goals, including the primary objective